OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden hours per response 11.00
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Lifeline Therapeutics, Inc.
-------------------------------------
(Name of Issuer)
Common Stock
------------------------------
(Title of Class of Securities)
53221T108
----------------------------
(CUSIP Number)
William Joseph Driscoll
Rosemary A Driscoll
6367 South Jamaica Street
Englewood, CO 80111
Telephone: 720 488 1711
--------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 26, 2004
--------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.
SCHEDULE 13D
CUSIP No. 53221T108 Page 2 of 6
--------------------------------------------------------------------------------
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes)
SCHEDULE 13D
CUSIP No. 53221T108 Page 3 of 6
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS. I.R.S. IDENTIFICATION NO.OF ABOVE PERSON
William Joseph Driscoll
Rosemary A. Driscoll
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
-------------------------------------------------------------------------(b) [ ]
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
William Joseph Driscoll: United States
Rosemary A. Driscoll: United States
--------------------------------------------------------------------------------
NUMBER OF | 7 | SOLE VOTING POWER
SHARES 0 shares
BENEFICIALLY -----------------------------------------------------
OWNED BY | 8 | SHARED VOTING POWER
EACH 5,033,800shares
REPORTING -----------------------------------------------------
PERSON | 9 | SOLE DISPOSITIVE POWER
WITH 0 shares
-----------------------------------------------------
| 10 | SHARED DISPOSITIVE POWER
5,033,800 shares
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,033,800 shares as joint tenants
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.7%
--------------------------------------------------------------------------------
SCHEDULE 13D
CUSIP No. 53221T108 Page 4 of 6
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
William Joseph Driscoll: IN
Rosemary A. Driscoll: IN
Item 1. Security And Issuer
This Statement relates to the Common Stock of Lifeline Therapeutics, Inc.,
a company organized under the laws of the State of Colorado.
The principal executive offices of the Company are located at 6400 South
Fiddlers Green Circle, Suite 1750, Englewood, Colorado 80111.
Item 2. Identity and Background
The identities and residential addresses of the reporting persons are:
William Joseph Driscoll, 6367 South Jamaica Street, Englewood, Colorado
80111; and
Rosemary A. Driscoll, 6367 South Jamaica Street, Englewood, Colorado 80111.
Mr. Driscoll serves as the President and a Director of Lifeline
Therapeutics, Inc., 6400 South Fiddlers Green Circle, Suite 1750, Englewood,
Colorado 80111.
Mrs. Driscoll currently is not employed.
The reporting persons have not been convicted in criminal proceedings of
the nature described in Item 2(d) of Schedule 13D in the last five years.
The reporting persons have not been parties to a civil proceeding of the
nature described in Item 2(e) of Schedule 13D in the last five years.
The reporting persons are both citizens of the United States.
SCHEDULE 13D
CUSIP No. 53221T108 Page 5 of 6
--------------------------------------------------------------------------------
Item 3. Source and Amount of Funds or Other Consideration
This Schedule 13D reports the following transactions:
-------------------------------------- -----------------------------------------
Securities Amount/Source of Funds
-------------------------------------- -----------------------------------------
5,623,800 shares of common stock Mr. Driscoll acquired the shares of
common stock pursuant to the terms of an
Agreement and Plan of Reorganization
between Lifeline Nutraceuticals
Corporation and Lifeline Therapeutics,
Inc., whereby the shareholders of
Lifeline Nutraceuticals exchanged their
outstanding common stock in Lifeline
Nutraceuticals for newly issued stock in
Lifeline Therapeutics, Inc.
-------------------------------------- -----------------------------------------
5,623,800 shares of common stock On October 29, 2004, Mr. Driscoll
transferred (as a gift) a joint tenancy
interest in the 5,623,800 shares of
Lifeline Therapeutics common stock to
his wife, Rosemary A. Driscoll.
-------------------------------------- -----------------------------------------
150,000 shares of common stock On November 1, 2004, Mr. and Mrs.
Driscoll transferred (as a gift) 150,000
shares of common stock to Joy and Mark
Driscoll as joint tenants.
-------------------------------------- -----------------------------------------
440,000 shares of common stock On November 1, 2004, Mr. and Mrs.
Driscoll transferred (as a gift) 440,000
shares of common stock to Luke Driscoll.
-------------------------------------- -----------------------------------------
Item 4. Purpose of Transaction
The reporting persons acquired these shares for investment purposes.
Item 5. Interest in the Securities of the Issuer
(a) The reporting persons aggregate interest and percentage of common stock
of Lifeline Therapeutics, Inc. equals 5,033,800 shares (30.7% of the shares of
common stock outstanding). The shares of common stock described above are the
only interest the reporting persons have in Lifeline Therapeutics, Inc. common
stock.
(b) The reporting persons, individually, do not have sole voting or sole
dispositive power with respect to any shares of common stock in Lifeline
Therapeutics, Inc. The reporting persons have shared voting and dispositive
power with respect to 5,033,800 shares of common stock of Lifeline Therapeutics,
Inc., which they hold as joint tenants.
(c) N/A
(d) N/A
(e) N/A
SCHEDULE 13D
CUSIP No. 53221T108 Page 6 of 6
-------------------------------------------------------------------------------
Item 6. Contract, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
None
Item 7. Material to be Filed as Exhibits
N/A
Signatures and Affidavits:
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: December 7, 2004 By: /s/ William Joseph Driscoll
-------------------------------------
Dated: December 7, 2004 By: /s/ Rosemary A. Driscoll
-------------------------------------
ATTENTION: Intentional misstatements or omissions of fact constitute federal
criminal violations. (See 18USC1001)